Tumor-host colluding through erythroid progenitor cells: Mechanisms and opportunities.

Immunotherapy, particularly immune checkpoint blockade (ICB), has shown great promise in the treatment of cancer and emerged as a beacon of hope for patients who have exhausted traditional therapeutic options. Despite ICB's approval for the treatment of advanced tumors, its efficacy remains limited to a small subset of patients. As a systemic disease, cancer can induce changes in the composition and function of the systemic immune system, and ICB resistance often involves a dialogue between the tumor microenvironment (TME) and the systemic immune macroenvironment. While investigations into tumor progression and ICB resistance have largely focused on the TME itself, the alterations in the systemic immune system and immune macroenvironment are still poorly understood. Given the spleen's role as the largest secondary lymphoid organ, its examination and discussion may provide valuable insights into the systemic immune status and TME components. Recent studies have highlighted the importance of the spleen in tumor progression and immunotherapy, particularly in the context of erythroid progenitor cells (EPCs), a significant cell subpopulation. In this review, we discuss the mechanisms and role of splenic extramedullary hematopoiesis (EMH) as an intermediary in tumor-host interactions and explore the mechanism of EPC-TME collusions. We further summarize the progress in EPC-targeting strategies and emphasize the potential for further research into the role and mechanisms of EPCs in tumor progression and treatment, which could have far-reaching implications.

• Publication year

  2023

• Venue

  Cancer Letters

• Publication date

  2023-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.canlet.2023.216193PMID 37088326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.

  2023cited by this paper
• Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study

  2022cited by this paper
• The role of erythrocytes and erythroid progenitor cells in tumors

  2022cited by this paper
• Hallmarks of Cancer: New Dimensions.

  2022cited by this paper
• Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy

  2022cited by this paper
• Normalizing the Immune Macroenvironment via Debulking Surgery to Strengthen Tumor Nanovaccine Efficacy and Eliminate Metastasis.

  2022cited by this paper
• Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy.

  2022cited by this paper
• Single-cell transcriptomic analysis identifies an immune-prone population in erythroid precursors during human ontogenesis

  2022cited by this paper
• Direct chemical reprogramming of human cord blood erythroblasts to induced megakaryocytes that produce platelets.

  2022cited by this paper
• Ultrasound-Targeted Microbubble Destruction: Modulation in the Tumor Microenvironment and Application in Tumor Immunotherapy

  2022cited by this paper
• Theranostic near-infrared-IIb emitting nanoprobes for promoting immunogenic radiotherapy and abscopal effects against cancer metastasis

  2021cited by this paper
• Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.

  2021cited by this paper
• Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.

  2021cited by this paper
• Systemic immunity in cancer

  2021cited by this paper
• Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity

  2021cited by this paper
• Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity

  2021cited by this paper
• Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development

  2021cited by this paper
• Ultrasound-Targeted Microbubble Destruction Alleviates Immunosuppression Induced by CD71+ Erythroid Progenitor Cells and Promotes PDL-1 Blockade Immunotherapy in the Lewis Lung Cancer Model

  2021cited by this paper
• Pharmacologic fibroblast reprogramming into photoreceptors restores vision

  2020cited by this paper
• ImmunoPET: Concept, Design, and Applications.

  2020cited by this paper
• Immune crosstalk in cancer progression and metastatic spread: a complex conversation

  2020cited by this paper
• Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules

  2020cited by this paper
• The mechanisms of pathological extramedullary hematopoiesis in diseases

  2020cited by this paper
• Thrombopoietin maintains cell numbers of hematopoietic stem and progenitor cells with megakaryopoietic potential

  2020cited by this paper
• Intratumoral CD45+CD71+ erythroid cells induce immune tolerance and predict tumor recurrence in hepatocellular carcinoma.

  2020cited by this paper
• Systemic dysfunction and plasticity of the immune macroenvironment in cancer models

  2020cited by this paper
• Splenic Hematopoietic and Stromal Cells in Cancer Progression

  2020cited by this paper
• Human splenic TER cells: A relevant prognostic factor acting via the artemin‐GFRα3‐ERK pathway in pancreatic ductal adenocarcinoma

  2020cited by this paper
• Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells

  2020cited by this paper
• Generation of Myeloid Cells in Cancer: The Spleen Matters

  2020cited by this paper
• Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis

  2020cited by this paper
• The Intersection between Tumor Angiogenesis and Immune Suppression

  2019cited by this paper
• Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints.

  2019cited by this paper
• Dangguibuxue decoction abolishes abnormal accumulation of erythroid progenitor cells induced by melanoma.

  2019cited by this paper
• Splenomegaly induced by anemia impairs T cell movement in the spleen partially via EPO.

  2019cited by this paper
• Tumour-intrinsic resistance to immune checkpoint blockade

  2019cited by this paper
• Prophylactic in vivo hematopoietic stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models.

  2019cited by this paper
• Chemical Cocktail Induces Hematopoietic Reprogramming and Expands Hematopoietic Stem/Progenitor Cells

  2019cited by this paper
• Structure and function of the immune system in the spleen

  2019cited by this paper
• Maturation-associated gene expression profiles during normal human bone marrow erythropoiesis

  2019cited by this paper
• Engineered immune cells as highly sensitive cancer diagnostics

  2019cited by this paper
• Treg-mediated acquired resistance to immune checkpoint inhibitors.

  2019cited by this paper
• The hypoxic tumour microenvironment

  2018cited by this paper
• VEGF expands erythropoiesis via hypoxia-independent induction of erythropoietin in noncanonical perivascular stromal cells

  2018cited by this paper
• Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis

  2018cited by this paper
• Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor Progression.

  2018cited by this paper
• CD71+ Erythroid Suppressor Cells Promote Fetomaternal Tolerance through Arginase-2 and PDL-1

  2018cited by this paper
• Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells

  2018cited by this paper
• Understanding the tumor immune microenvironment (TIME) for effective therapy

  2018cited by this paper
• The hallmarks of successful anticancer immunotherapy

  2018cited by this paper
• Reactive Oxygen Species: Involvement in T Cell Signaling and Metabolism.

  2018cited by this paper
• Myeloid-Derived Suppressor Cells

  2017cited by this paper
• TGF-β inhibitors stimulate red blood cell production by enhancing self-renewal of BFU-E erythroid progenitors.

  2016cited by this paper
• Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche.

  2016cited by this paper
• Targeting STAT3 signaling reduces immunosuppressive myeloid cells in head and neck squamous cell carcinoma

  2016cited by this paper
• The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

  2016cited by this paper
• Tumor microenvironment: The culprit for ovarian cancer metastasis?

  2016cited by this paper
• LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma

  2016cited by this paper
• Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response

  2015cited by this paper
• Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers

  2015cited by this paper
• Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients

  2014cited by this paper
• VEGFR2-mediated vascular dilation as a mechanism of VEGF-induced anemia and bone marrow cell mobilization.

  2014cited by this paper
• Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis

  2014cited by this paper
• STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

  2014cited by this paper
• GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling

  2014cited by this paper
• NADPH oxidases: an overview from structure to innate immunity-associated pathologies

  2014cited by this paper
• The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis

  2014cited by this paper
• The spleen in local and systemic regulation of immunity.

  2013cited by this paper
• Abstract 1623: PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells.

  2013cited by this paper
• A pivotal role of bone remodeling in granulocyte colony stimulating factor induced hematopoietic stem/progenitor cells mobilization

  2013cited by this paper
• Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infection

  2013cited by this paper
• Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms

  2013cited by this paper
• Macrophages support pathological erythropoiesis in Polycythemia Vera and Beta-Thalassemia

  2013cited by this paper
• IRP1 regulates erythropoiesis and systemic iron homeostasis by controlling HIF2α mRNA translation.

  2013cited by this paper
• Up-regulated expression of CXCL12 in human spleens with extramedullary haematopoiesis

  2013cited by this paper
• Role of the adaptor protein LNK in normal and malignant hematopoiesis

  2013cited by this paper
• Splenectomy for Massive Splenomegaly: Long-Term Results and Risks for Mortality

  2013cited by this paper
• Angiotensin II drives the production of tumor-promoting macrophages.

  2013cited by this paper
• Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo.

  2013cited by this paper
• Extramedullary Hematopoiesis: A New Look at the Underlying Stem Cell Niche, Theories of Development, and Occurrence in Animals

  2012cited by this paper
• Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.

  2012cited by this paper
• Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.

  2012cited by this paper
• Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

  2012cited by this paper
• Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.

  2012cited by this paper
• Regulation of erythropoietin production

  2011cited by this paper
• Hematopoietic stem and progenitor cell trafficking.

  2011cited by this paper
• The many roles of NOX2 NADPH oxidase-derived ROS in immunity

  2010cited by this paper
• The MAPK ERK1 is a negative regulator of the adult steady-state splenic erythropoiesis.

  2010cited by this paper
• The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms.

  2010cited by this paper
• Iron control of erythroid development by a novel aconitase-associated regulatory pathway.

  2010cited by this paper
• Artemin is oncogenic for human mammary carcinoma cells

  2009cited by this paper
• Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence.

  2008cited by this paper
• Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells

  2008cited by this paper
• Impact of Splenectomy in Patients with Gastric Adenocarcinoma of the Cardia

  2007cited by this paper
• The significance of inadvertent splenectomy during colorectal cancer resection.

  2007cited by this paper
• Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches.

  2006cited by this paper
• IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis.

  2005cited by this paper
• The anaemia of cancer: death by a thousand cuts

  2005cited by this paper
• Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species1

  2004cited by this paper
• Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins.

  2003cited by this paper

• Epigenetic Reprogramming of Erythroid Progenitor Cells: Insights for Enhancing Cancer Immunotherapy

  2026cites this paper
• The Combined Prognostic Value of 18 F‐FDG PET/CT Metabolic Parameters of Immune Organs and Hematological Immune‐Related Markers in Patients With Locally Advanced Cervical Cancer

  2025cites this paper
• Comprehensive pan-cancer analysis of KRT6A as a prognostic and immune biomarker

  2025cites this paper
• Turning cold tumors into hot tumors to ignite immunotherapy

  2025cites this paper
• Erythroid Cells as Full Participants in the Tumor Microenvironment

  2023cites this paper
• Targeting the epigenome to reinvigorate T cells for cancer immunotherapy

  2023cites this paper